Sana Biotechnology’s (SANA) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright restated their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a research report released on Monday morning,Benzinga reports. HC Wainwright currently has a $8.00 target price on the stock.

SANA has been the topic of a number of other research reports. JMP Securities downgraded Sana Biotechnology from an “outperform” rating to a “market perform” rating in a report on Tuesday, November 5th. Citigroup raised their target price on Sana Biotechnology from $8.00 to $15.00 and gave the company a “buy” rating in a report on Friday, August 9th.

Sana Biotechnology Price Performance

Sana Biotechnology stock opened at $2.89 on Monday. The stock’s fifty day moving average price is $4.14 and its two-hundred day moving average price is $5.73. Sana Biotechnology has a one year low of $2.76 and a one year high of $12.00. The firm has a market cap of $642.93 million, a PE ratio of -2.06 and a beta of 1.44.

Sana Biotechnology (NASDAQ:SANA) last issued its earnings results on Friday, November 8th. The company reported ($0.25) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.26) by $0.01. Sell-side analysts expect that Sana Biotechnology will post -1.13 earnings per share for the current fiscal year.

Insider Activity at Sana Biotechnology

In related news, Director Richard Mulligan sold 150,000 shares of the firm’s stock in a transaction on Tuesday, September 24th. The stock was sold at an average price of $4.08, for a total transaction of $612,000.00. Following the sale, the director now owns 2,848,121 shares of the company’s stock, valued at $11,620,333.68. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 31.10% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Blue Trust Inc. lifted its holdings in Sana Biotechnology by 1,246.6% during the 3rd quarter. Blue Trust Inc. now owns 13,129 shares of the company’s stock worth $55,000 after buying an additional 12,154 shares during the period. Algert Global LLC acquired a new position in Sana Biotechnology during the 2nd quarter worth about $73,000. Cornercap Investment Counsel Inc. acquired a new position in Sana Biotechnology during the 3rd quarter worth about $67,000. XTX Topco Ltd acquired a new position in Sana Biotechnology during the 2nd quarter worth about $100,000. Finally, Dark Forest Capital Management LP lifted its holdings in Sana Biotechnology by 112.0% during the 2nd quarter. Dark Forest Capital Management LP now owns 27,314 shares of the company’s stock worth $149,000 after buying an additional 14,430 shares during the period. 88.23% of the stock is owned by institutional investors and hedge funds.

About Sana Biotechnology

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.